🧪Every single penny we raise directly funds #IB

🧪Every single penny we raise directly funds #IBDresearch projects throughout the UK, to improve the lives of people… https://t.co/LRHfxuW8k7

“A growing share of the drugs bill… now goes o

“A growing share of the drugs bill… now goes on a class of drugs called ‘#biologics’… near-copies — called… https://t.co/gl7uG5vCLV

Daily Updates on Generic Entry, Litigation, Biosimilars, and more with the DrugPatentWatch Daily Briefing. Sign up… https://t.co/qlf03zBVsX

Dr Yiu is now taking questions. If you’d like to learn more about the study please see our website:… https://t.co/Oc8slQezY4

@BADBIR Dr Yiu – Some people have anecdotally reported worsening symptoms or side effects from biosimilars as compa… https://t.co/VVb0hxnwF7

Dr Yiu – Biosimilars do not have to be tested in the same way as originator medicines, though they have to prove they work in the same way.

Dr Yiu – Biosimilars have really helped to reduce cost to the NHS which is good news as more people can access the treatment

Next we have Dr Zenas Yiu from @OfficialUoM presenting his study using data from @BADBIR to describe the current us… https://t.co/vRfwcmuMLk

Have you joined the #IBDSuperHeroes Facebook group?⁠
⁠
2K wonderful #IBDWarriors – Great for chats, tips, rants & j… https://t.co/JwDbb4dzBR

Register now to the MENA Pharma Manufacturing Virtual Series and learn from Mr. Waleed Al-Shaqha as he talks about… https://t.co/JKaXnaSgqm